Guardant Health, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report (Form 8-K) was filed on October 9, 2018, by Guardant Health, Inc., a Delaware corporation. The filing documents corporate governance amendments and the completion of the Company's Initial Public Offering (IPO) on the same date.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, or debt levels. The only financial data disclosed relates to the capital raise:
- Shares Sold: 14,375,000 shares of common stock.
- Offering Price: $19.00 per share.
- Total Proceeds: The filing indicates the full exercise of the underwriters' option to purchase additional shares was included in the share count, but does not explicitly state the net proceeds after underwriting discounts.
Material Changes
The primary material change is the transition from a private to a public company via the IPO. Additionally, the Company amended its Articles of Incorporation and Bylaws to:
- Increase authorized common stock to 350,000,000 shares.
- Eliminate all references to previously existing preferred stock and authorize 10,000,000 shares of undesignated preferred stock.
- Establish a classified board of directors with staggered three-year terms.
- Restrict stockholder actions by written consent and the ability to call special meetings.
- Designate the Court of Chancery of Delaware as the exclusive forum for certain corporate actions and U.S. federal district courts for Securities Act claims.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard legal designations for litigation forums. The document focuses strictly on the mechanics of the IPO closing and the resulting corporate charter changes.
Investor Verification Checklist
- Verify the final net proceeds from the IPO after deducting underwriting fees and offering expenses.
- Review the full text of the Amended and Restated Certificate of Incorporation (Exhibit 3.1) and Bylaws (Exhibit 3.2) to understand specific governance restrictions.
- Confirm the exact number of shares issued upon the full exercise of the underwriters' option versus the base offering.
- Check subsequent filings (e.g., S-1/A or 10-K) for detailed financial statements and risk factors not included in this 8-K.